Navellier & Associates Inc Genmab A/S Transaction History

Navellier & Associates Inc

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 09, 2023	BUY	$35.27 - $42.24 $52,375 - $62,726	1,485 Added 6.16%	25,600 $902,000
Q2 2023 Aug 07, 2023	BUY	$37.4 - $42.94 $55,763 - $64,023	1,491 Added 6.59%	24,115 $916,000
Q1 2023 May 12, 2023	SELL	$34.88 - $43.22 $14,231 - $17,633	-408 Reduced 1.77%	22,624 $854,000
Q4 2022 Feb 02, 2023	BUY	$33.8 - $47.06 $778,481 - $1.08 Million	23,032 New	23,032 $976,000
Q2 2021 Aug 09, 2021	SELL	$32.88 - $44.57 $3.34 Million - $4.52 Million	-101,518 Closed	0 $0
Q1 2021 May 12, 2021	SELL	$30.92 - $44.4 $182,397 - $261,915	-5,899 Reduced 5.49%	101,518 $3.33 Million
Q4 2020 Feb 05, 2021	SELL	$33.66 - $40.76 $107,812 - $130,554	-3,203 Reduced 2.9%	107,417 $4.37 Million
Q3 2020 Nov 09, 2020	BUY	$33.07 - $38.68 $8,465 - $9,902	256 Added 0.23%	110,620 $4.05 Million
Q2 2020 Aug 12, 2020	BUY	$20.05 - $33.89 $1.69 Million - $2.86 Million	84,340 Added 324.09%	110,364 $3.74 Million
Q1 2020 May 13, 2020	SELL	$17.15 - $25.22 $49,975 - $73,491	-2,914 Reduced 10.07%	26,024 $551,000
Q4 2019 Feb 12, 2020	BUY	$18.88 - $24.14 $546,349 - $698,563	28,938 New	28,938 $646,000

236

52.5M

10.2K

25.5K

Ticker GMAB
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 658,292,992
Market Cap $13.6B
Description
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphoc...

Get notified when there are updates to the investment portfolio of Navellier & Associates Inc, based on Form 13F filings with the SEC.

Stay updated on Navellier & Associates Inc with notifications on news.